Summit C-Suite Risks Success, Akeso Wins Either Way

Akeso has a validated process in place for developing antibodies but does require US exposure to meet its lofty valuation.

Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-Shaw

Biocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to ...
Fierce Biotech

Pfizer's mRNA flu vaccine shows 34.5% greater efficacy than standard shot in phase 3

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...
STAT

An experimental flu shot & a nasty flu season?

Lots more details about the fallout from STAT’s John Wilkerson. Read more here.
Newser on MSN

Pfizer's New Flu Shot Could Be a 'Game Changer'

A new mRNA-based flu vaccine from Pfizer has shown greater effectiveness than the standard flu shot in a large Phase 3 trial, according to results published in the New England Journal of Medicine. The ...